ABBV AbbVie
- 162.930
- -1.630-0.99%
- 162.790
- -0.140-0.09%
AbbVie News
AbbVie | 8-K/A: Poll Results of AbbVie Meeting (Amendment)
AbbVie | 8-K: AbbVie Reports First-Quarter 2024 Financial Results
AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
AbbVie | DEF 14A: Definitive information statements
AbbVie | DEFA14A: Others
AbbVie | PRE 14A: Preliminary proxy statements relating to merger or acquisition
AbbVie | 8-K: Closure of Notes Sale Pursuant to Underwriting Agreement
AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
AbbVie | 8-K: AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
AbbVie | 8-K: AbbVie Completes Acquisition of ImmunoGen
AbbVie | 8-K: AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited)
AbbVie | 8-K: AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
AbbVie | 8-K: Abbvie to Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio
AbbVie | 8-K: AbbVie Reports Third-Quarter 2023 Financial Results
AbbVie | 8-K: Abbvie Appointed Jennifer Davis as a Class II Director and Susan Quaggin as a Class III Director
AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
AbbVie | 8-K: AbbVie Reports Second-Quarter 2023 Financial Results
AbbVie | 8-K: The Impact of Acquired IPR&D and Milestones Expense
AbbVie | 8-K: Robert A. Michael has been appointed President and Chief Operating Officer
Analysis
Price Target
No Data
